Penserra Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Penserra Capital Management’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.1M	Sell	806,888 -68,238	-8%	-$1.14M	0.15%	171
2025 Q4	$14.7M	Buy	875,126 +80,988	+10%	+$1.36M	0.17%	153
2025 Q3	$12.3M	Buy	794,138 +24,481	+3%	+$335K	0.15%	161
2025 Q2	$9.86M	Buy	769,657 +22,736	+3%	+$280K	0.14%	184
2025 Q1	$9.48M	Sell	746,921 -80,654	-10%	-$1.09M	0.17%	161
2024 Q4	$10.9M	Buy	827,575 +51,573	+7%	+$744K	0.2%	151
2024 Q3	$11.7M	Buy	+776,002	New	+$11.7M	0.25%	97

Other funds holding HQL

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Penserra Capital Management's HQL Position: Q1 2026 in Review

Penserra Capital Management reduced its abrdn Life Sciences Investors (HQL) stake by 7.8% in Q1 2026, selling an estimated $1.14M and leaving 806,888 shares worth $13.1M. The position accounts for 0.15% of the portfolio, ranked #171.

Penserra Capital Management first reported a position in HQL in Q3 2024 and has held it in 7 quarters since. The position peaked at $14.7M in Q4 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

Penserra Capital Management held 806,888 shares of abrdn Life Sciences Investors worth $13.1M as of Q1 2026.
Penserra Capital Management sold 68,238 abrdn Life Sciences Investors shares in Q1 2026, an estimated $1.14M.
abrdn Life Sciences Investors made up 0.15% of Penserra Capital Management's portfolio in Q1 2026, its #171 holding.
Penserra Capital Management first reported a position in abrdn Life Sciences Investors in Q3 2024 and has held it in 7 quarters since.
Penserra Capital Management's abrdn Life Sciences Investors position peaked at $14.7M in Q4 2025.
86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.